Stocks to watch, Nov 5: NHPC, Nykaa, BSE, Dabur, Britannia, Bharti Airtel, Mahindra and Mahindra, Titan, LIC

The domestic stock market is expected to open sharply higher on Thursday, November 5, with GIFT NIFTY futures indicating a gap-up opening for the benchmark NIFTY50 index.

GIFT NIFTY futures suggest that the NIFTY50 could open around 305 points higher.

The list includes Titan Company, LIC, Bharti Airtel, Mahindra & Mahindra, ONGC, Samvardhana Motherson International, Britannia Industries, LG Electronics India, Bharat Forge, Berger Paints India, Mphasis and Godfrey Phillips India, among others.

Nykaa had posted net profit of around ₹33 crore in the same period a year ago.

The consolidated revenue from operations of Nykaa grew by about 28% to ₹3,006 crore during the reported quarter from ₹2,345.98 crore in the September 2025 quarter.

Speaking on this quarter’s results, Falguni Nayar, Executive Chairperson, Founder and CEO of Nykaa, said, “Our performance this quarter reflects the strength of the Nykaa ecosystem, with each of our businesses contributing to growth and productivity gains. We continued to improve operational efficiency, particularly across marketing and overheads."

The company had logged a net profit of ₹444.79 crore in July-September FY26, Dabur India said in a regulatory filing.

Revenue from operations was up 11.64% at ₹3,563.07 crore in Q2 FY27 from ₹3,191.32 crore a year ago.

Total expenses were at ₹3,089.14 crore in the September quarter, up 12% year-on-year.

This reflects the underlying strength of its core brands, continued momentum in the premium portfolio, and focused execution across categories, the company said.

The arrangement, executed through Thakral’s Indian subsidiary TIL Investments Pvt Ltd, is structured as a long-term land lease for an initial period of around 30 years, Manipal Health informed stock exchanges.

The proposed facility will be developed in phases, with the first phase expected to have up to 500 beds. Thakral also plans to develop an integrated health and wellness ecosystem around the flagship hospital, supported by retail and hospitality offerings.

Dilip Jose, CEO of Manipal Hospitals, stated that Delhi-NCR is an important market for the chain, and the new hospital will help strengthen its regional presence and serve local healthcare needs.

Consolidated revenue from operations grew about 18% to ₹1,242.26 crore during the reported quarter, up from ₹1,051.24 crore in the September 2025 quarter, Physicswallah (PW) said in a statement.

"We delivered record revenue and a sharp improvement in profitability, while our learner base kept widening across K-12, vernacular and new categories. Our focus remains on scaling affordable, tech-lededucation with disciplined capital allocation," PW, Founder and CEO, Alakh Pandey, said in a statement.

The company recorded growth of over 30% in NEET enrolments during the second quarter as demand delayed by the NEET UG postponement came through. PW's online revenue grew 26.4% YoY to ₹694 crore, and Offline revenue grew 9% YoY to ₹541 crore during the reported quarter.

The company's PAT was ₹22.2 crore a year ago, according to a regulatory filing.

Its revenue from operations dipped 22.9% during the quarter under review to ₹794.1 crore compared to ₹1,029 crore in the year-ago period.

The company's textiles and related products and digital infrastructure businesses continued to be the key growth drivers during the quarter.

"Our focus remains on strengthening the quality and composition of our business portfolio while positioning Mafatlal Industries for its next phase of growth.

It had posted a profit after tax (PAT) of ₹848.13 crore during the same period of the previous fiscal.

The company posted its highest-ever quarterly revenue from operations at ₹10,263 crore, up 24% year-on-year, Aurobindo Pharma said in a regulatory filing.

The company's expenses also rose to ₹8,740.9 crore from ₹7,132.03 crore a year earlier, it said.

Its US revenue increased 25% to ₹4,555 crore, while the Europe business jumped 27% to ₹3,161 crore during the quarter under review, the company said in a release.

As of September 30, on a cumulative basis, the company filed 900 Abbreviated New Drug Applications (ANDAs) with the US health regulator and received 747 final approvals and 35 tentative approvals.

The exchange posted a net profit of ₹557 crore in the year-ago period.

In the equity cash segment, BSE recorded its highest-ever quarterly Average Daily Turnover (ADTV) of ₹10,494 crore in Q2 FY27, suggesting sustained market participation.

BSE derivatives recorded average daily premium turnover of ₹22,531 crore in the second quarter of FY27.

Momentum strengthened further in October, with monthly index options premium ADTV reaching an all-time high of ₹35,481 crore.

The consolidated net profit was ₹1,219.28 crore in the quarter ended on September 30, 2025, an exchange filing showed.

Total income rose to ₹4,669.58 crore in the quarter from ₹3,629.98 crore in the same period a year ago.

The state-owned company had earned a net profit of ₹710 crore in the year-ago period.

The company's total income rose to ₹4,051 crore in the second quarter of this fiscal year from ₹3,251 crore in the corresponding period of the preceding financial year, HUDCO said in a regulatory filing.

HUDCO is a premier techno-financing public sector enterprise in the field of housing and infrastructure development.

The company earned interest income of ₹4,023 crore in Q2 FY27, against ₹3,197 crore a year ago.

The transport infrastructure consultancy and engineering company had posted a net profit of ₹109.10 crore for the year-ago period.

Revenue from operations increased to ₹582.81 crore from ₹578.83 crore a year ago, RITES said in a regulatory filing.

Total expenses were up to ₹452.8 crore as against ₹436.74 crore in the corresponding quarter of the previous fiscal year.

Rahul Mithal, Chairman and Managing Director, RITES, said the performance in the quarter was muted, with certain planned revenue milestones sliding marginally into Q3.

Its net profit stood at ₹53.89 crore in the year-ago period.

Total income rose to ₹1,909.84 crore in the second quarter of the current fiscal from ₹1,679.49 crore in the corresponding period of the preceding financial year, according to a regulatory filing.

During the April-September period of the 2026-27 fiscal, the company's profit increased to $146.43 crore from ₹105.46 crore in the year-ago period.

Total income grew to ₹3,561.55 crore in the first half of this fiscal from ₹3,228.07 crore in the corresponding period of the preceding financial year.

The company said it had delivered a PAT of ₹51 crore in the second quarter of FY 26.

Revenue for Q2 FY27 rose 19% to ₹771 crore compared to ₹646 crore in the September quarter of the last fiscal.

The company said it saw a significant uptick in execution momentum despite a monsoon-impacted quarter.

Gross debt as of September 30, 2026, stood at ₹540 crore, with gross debt-to-equity at 0.27x, and net debt to equity at 0.18x, Capacit'e said.

The company had logged a net profit of ₹80.63 crore in July-September period a year ago, according to a regulatory filing from JK Lakshmi Cement Ltd (JKLC), a flagship company of JK Organisation.

Revenue from operations was up at ₹1,616.92 crore as against ₹1,531.77 crore in the corresponding period last year. Total expenses were higher by 10% at ₹1,598.29 crore.

Sales volume was up 5% to 2.98 million tonne in the second quarter of FY27. Total income, which includes other income, was higher by 4.66% to ₹1,626.88 crore.

The Vadodara-headquartered company had posted a net profit (attributable to owners of the company) of ₹184.7 crore in the year-ago period, according to a regulatory filing.

Alembic Pharma’s revenue from operations rose 36.3% to ₹2,603.48 crore, up from ₹1,910.15 crore in Q2 FY26.

Sequentially, profit and revenue were up by 94% and 21%, respectively.

The company's US formulations business led the revenue growth with a rise of 77%, aided by a surge in volume and new launches.

The pharma major further announced the expansion of its strategic collaboration with DifGen Pharmaceuticals (DifGen) to grow its complex generics portfolio in the US market.